Clinical trial

A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis

NCT01412333

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2011-09-20

PhasePHASE3

Study timeline

Study start (actual)2011-09-20Date precision: day

Registry last updated2024-03-08

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Relapsing Multiple Sclerosisunresolved

Interventions

Interferon beta-1aDRUG · verified · RxNorm: interferon beta-1a

Ocrelizumab-matching placeboDRUG

OcrelizumabDRUG · verified · RxNorm: ocrelizumab

Interferon beta-1a-matching placeboDRUG

Sponsors & collaborators

Hoffmann-La Rochelead sponsor

Mapped research locations

SofiaBulgaria4 IstanbulTurkey (Türkiye)3 San AntonioTexas, United States2 MadridSpain2 BarcelonaSpain2 MontrealQuebec, Canada2 StockholmSweden2 LodzPoland2 MünchenGermany2 ZagrebCroatia2 New YorkNew York, United States1 HoustonTexas, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01412333 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.